Rebirth Biotech Nabs ¥50M in Series A Funding to Test Cell Therapies

On April 19, 2019, Rebirth Biotech, a newly launched biotech company has secured 50 million yuan in series A funding. Five companies participated in the investment, including China SME Development Fund, Huade Capital and Red Star Macalline.

As a high-tech enterprise, Rebirth Biotech owns two leading national GMP standard laboratories and China's top R&D expert teams. It has a number of global breakthroughs technology patents and independent intellectual property rights, as well as professional biomedical technology and independent research and development capabilities.

In November 2018, Rebirth Biotech signed a contract with the authoritative 3 Grade Class A Hospital to jointly establish the "Institute of integrated cell medicine of traditional Chinese and western medicine" and build GMP cell clinical laboratory no.2 to conduct clinical research translation.

After testing and evaluating the global market for cell biology applications and technology transformation, Rebirth Biotech has the absolute advantage in the field of cell biology patent technology. Based on the above background and technical strength, Rebirth Biotech began to prepare for A round of financing in November 2018 after mastering the resource reserve that is relatively suitable for expanding the scale.

After A round of financing, Rebirth Biotech acquired the relevant cell products listed in the United States and went through the Phase III clinical trials. And the company will prepare clinical approval and large-scale market promotion and application in China.

The declaration of biological cell drugs was announced in early April 2019. In the future, Rebirth Biotech will continue to adhere to the corporate vision and mission of "building a vibrant society and making human beings beautiful due to health".

About China SME Development Fund

China set up a special fund of RMB60 billion (US$9.4 billion) to support small and medium-sized enterprises (SMEs) in the country. This fund, under a public-private partnership structure, will focus on providing early-stage and growth capital to small and medium-sized enterprises across China.

Shenzhen Capital Group, which won the mandate to manage the vehicle after winning a public auction, has established a new team to manage the fund. The members of this team are not allowed to work for the company's other funds.

The national small and medium-sized enterprises development fund will operate independently, free from government influences, says the reports.

Red Star Macalline is a furniture retailer in China. Red Star Macalline operates about 300 shopping malls and 364 home improvement centers throughout China, leasing space to retailers in addition to selling its own inventory and services, including interior decoration consultations and construction. The company will work together with Alibaba to improve its physical stores and take advantage of the latter’s e-commerce channels.